Eryvac Data Sheet

Presentation:

An opaque fluid vaccine prepared from formalin killed cultures of Erysipelothrix rhusiopathiae serotype 2, strains CN3342 and CN3461, and serotype 1, strain P15/10, (at least 3.3 x 10⁸ cells/ml/strain) adsorbed onto aluminium hydroxide. 0.013% Thiomersal is added as preservative.

Uses:

Sheep: 

It has been demonstrated under field conditions that the vaccine is suitable:

For the passive immunisation of lambs born to fully vaccinated ewes to reduce clinical signs of polyarthritis and erysipelas septicaemia associated with Ery.rhusiopathiae  infection.

For the active immunisation of sheep to reduce clinical signs of post-dipping lameness.

Turkeys: 

For the active immunisation of turkeys of up to 24 weeks of age to reduce clinical signs of disease due to Ery.rhusiopathiae serotype 3 infections.

Dosage and administration:

It is recommended that an automatic vaccinator is used.   Since the bottle containing this product is non-collapsible a vaccinator with a vented draw-off spike or similar device must be used. The instructions supplied with such syringes should be noted and care should be taken to ensure the delivery of the full dose, particularly with the final few doses from the bottle.

The vaccine may be administered using a sterile needle and syringe, providing a fresh sterile needle is used each time the rubber cap is punctured to avoid contamination of the remaining contents. Syringes and needles must be from gamma irradiated packs or freshly sterilised by boiling for at least 20 minutes. No alcohol or other disinfectants should be used for sterilisation. 

The vaccine bottle must be shaken well before use. Once opened, use of the vaccine must be completed within 10 hours. Partially used containers must be discarded at the end of each day’s operations.

Partly used and empty packs, syringes and needles must be disposed of in accordance with the requirements for clinical waste.

Sheep

2ml by subcutaneous injection in the loose skin on the side of the neck, observing aseptic precautions.

Primary vaccination: 

Pregnant ewes:  To reduce clinical signs of polyarthritis and erysipelas septicaemia associated with Ery.rhusiopathiae infection in lambs, pregnant ewes should be given two 2ml doses of Eryvac, separated by an interval of 3 weeks. The second injection should be given at least three weeks before the expected date of lambing.

Adult sheep and lambs: To reduce clinical signs of post-dipping lameness, adult sheep and lambs from about 8 weeks of age should be given two 2ml doses of Eryvac, separated by an interval of 3 weeks. 

The second injection should be given at least 2-3 weeks before the known period of risk of disease (e.g. following clipping and dipping).

Booster doses:

The full duration of protection has not been established, therefore after completion of the primary vaccination course, a 2ml booster dose must be given at either 12 month intervals or otherwise 2-3 weeks prior to a known period of disease risk, whichever is the shorter. Incidences of post-dipping lameness in sheep generally occur as a sequel to clipping or dipping. Fully vaccinated breeding ewes must receive a pre-lambing 2ml booster dose at least 3 weeks pre-lambing in order to provide aid in the control of polyarthritis and erysipelas septicaemia in lambs via colostrum. 

Turkeys

0.5ml by intramuscular injection into the breast muscle.

Primary vaccination:

Turkeys should be vaccinated with 0.5ml of Eryvac at 6 weeks of age. This should be repeated after an interval of 4 weeks. The immunity developed following this vaccination schedule should persist up to 24 weeks of age.

Contra-indications, warnings etc:

As with all vaccines, occasional hypersensitivity reactions may occur.

Eryvac is an inactivated vaccine containing an adjuvant, and as with most adjuvanted vaccines, vaccination may result in transient (2-3 days duration) soft, non-painful swellings at the injection site. 

Subcutaneous nodules, persisting for at least 2-3 weeks, occurred in pigs inoculated with a similar vaccine. Vaccination with Eryvac could be expected to  result in such lesions in the muscle tissue of turkeys or subcutaneous tissue in sheep, but no data are available on the nature and persistence of any lesions.

Not to be used for turkeys in lay and/or within 4 weeks before the onset of the laying period.

No information is available on the effects of the concurrent use of Eryvac with any other vaccine. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with the product. 

If in doubt, advice should be sought from a veterinary surgeon.

In any group of animals, a small number of individuals may fail to respond to vaccination as a result of immunological incompetence or for some other reason. Satisfactory immune responses will only be attained in healthy animals, thus it is important to avoid vaccination of animals which have intercurrent disease or which have poor nutritional status. As with most killed vaccines, significant levels of immunity cannot be expected until 2 weeks after the second dose of the primary vaccination course.

When vaccinating animals, stress should be avoided.

Withdrawal Period: Zero days

FOR ANIMAL TREATMENT ONLY. KEEP OUT OF REACH AND SIGHT OF CHILDREN.

Pharmaceutical precautions:

Store at +2°C to +8°C in the dark. Do not freeze. Use before the expiry date printed on the pack.

Disposal advice

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Legal category:

POM-VPS          To be supplied only on veterinary prescription

Package quantities:

50ml and 100ml polyethylene multidose bottles.

Further information

Nil

Marketing Authorisation number:

Vm 01708/4476       UK Authorised veterinary medicinal product

MA Holder:

Intervet UK Ltd

Walton Manor, Walton

Milton Keynes, Bucks

MK7 7AJ

Date of Preparation: 

28/06/06